192 related articles for article (PubMed ID: 26891890)
1. Nitric oxide signaling in human ovarian cancer: A potential therapeutic target.
El-Sehemy A; Postovit LM; Fu Y
Nitric Oxide; 2016 Apr; 54():30-7. PubMed ID: 26891890
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.
Zhao L; Yu C; Zhou S; Lau WB; Lau B; Luo Z; Lin Q; Yang H; Xuan Y; Yi T; Zhao X; Wei Y
Oncotarget; 2016 Jan; 7(2):1408-20. PubMed ID: 26593252
[TBL] [Abstract][Full Text] [Related]
3. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
4. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer.
Li L; Zhu L; Hao B; Gao W; Wang Q; Li K; Wang M; Huang M; Liu Z; Yang Q; Li X; Zhong Z; Huang W; Xiao G; Xu Y; Yao K; Liu Q
Oncotarget; 2017 May; 8(20):33047-33063. PubMed ID: 28380434
[TBL] [Abstract][Full Text] [Related]
5. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide donors reduce the invasion ability of ovarian cancer cells in vitro.
Kielbik M; Szulc I; Brzezinska M; Bednarska K; Przygodzka P; Sulowska Z; Nowak M; Klink M
Anticancer Drugs; 2014 Nov; 25(10):1141-51. PubMed ID: 25035962
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of nitric oxide donors impact on cisplatin resistance in various ovarian cancer cell lines.
Kielbik M; Szulc-Kielbik I; Nowak M; Sulowska Z; Klink M
Toxicol In Vitro; 2016 Oct; 36():26-37. PubMed ID: 27427240
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide donors for prostate and bladder cancers: Current state and challenges.
Seabra AB; Durán N
Eur J Pharmacol; 2018 May; 826():158-168. PubMed ID: 29501865
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.
Frederiksen LJ; Sullivan R; Maxwell LR; Macdonald-Goodfellow SK; Adams MA; Bennett BM; Siemens DR; Graham CH
Clin Cancer Res; 2007 Apr; 13(7):2199-206. PubMed ID: 17404104
[TBL] [Abstract][Full Text] [Related]
10. Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs.
Bonavida B
Biochem Pharmacol; 2020 Jun; 176():113913. PubMed ID: 32173364
[TBL] [Abstract][Full Text] [Related]
11. [Advances in the study of nitric oxide-donating drugs].
Zhang YH; Peng SX
Yao Xue Xue Bao; 2009 Nov; 44(11):1200-10. PubMed ID: 21355319
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide donors: spermine/NO and diethylenetriamine/NO induce ovarian cancer cell death and affect STAT3 and AKT signaling proteins.
Kielbik M; Klink M; Brzezinska M; Szulc I; Sulowska Z
Nitric Oxide; 2013 Nov; 35():93-109. PubMed ID: 24055735
[TBL] [Abstract][Full Text] [Related]
13. Are NHE1 and inducible nitric oxide synthase involved in human ovarian cancer?
Sanhueza C; Araos J; Naranjo L; Barros E; Toledo L; Subiabre M; Toledo F; Gutiérrez J; Chiarello DI; Pardo F; Leiva A; Sobrevia L
Pharmacol Res; 2016 Mar; 105():183-5. PubMed ID: 26821117
[No Abstract] [Full Text] [Related]
14. The regulation of nitric oxide in tumor progression and therapy.
Hu Y; Xiang J; Su L; Tang X
J Int Med Res; 2020 Feb; 48(2):300060520905985. PubMed ID: 32090657
[TBL] [Abstract][Full Text] [Related]
15. Production of nitric oxide and expression of inducible nitric oxide synthase in ovarian cystic tumors.
Nomelini RS; de Abreu Ribeiro LC; Tavares-Murta BM; Adad SJ; Murta EF
Mediators Inflamm; 2008; 2008():186584. PubMed ID: 19132106
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis.
Burke AJ; Garrido P; Johnson C; Sullivan FJ; Glynn SA
Antioxid Redox Signal; 2017 Jun; 26(18):1078-1090. PubMed ID: 28326819
[TBL] [Abstract][Full Text] [Related]
17. Assessing the predictive response of a simple and sensitive blood-based biomarker between estrogen-negative solid tumors.
Mohan S; Patel S; Barlow D; Rojas AC
Adv Med Sci; 2020 Sep; 65(2):424-428. PubMed ID: 32919119
[TBL] [Abstract][Full Text] [Related]
18. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
[TBL] [Abstract][Full Text] [Related]
19. Antitumoral Activity Of Nitric Oxide-Releasing Compounds.
Klink M; Kielbik M; Kielbik IS; Przygodzka P; Sulowska Z
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162287
[TBL] [Abstract][Full Text] [Related]
20. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
